{
    "nct_id": "NCT03443024",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis",
    "inclusion_criteria": "* Male or female, 18 years or older.\n* Chronic AD as defined by Hanifin and Rajka (1980) that has been present for ≥1 year before the screening visit .\n* Eczema Area and Severity Index (EASI) score ≥16 at the screening and the baseline visit.\n* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the screening and the baseline visit.\n* ≥10% body surface area (BSA) of AD involvement at the screening and the baseline visit.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with any of the following agents within 4 weeks prior to the baseline visit:\n* Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)\n* Phototherapy and photochemotherapy (PUVA) for AD.\n* Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 week prior to the baseline visit.\n* Treatment with:\n* An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, prior to the baseline visit.\n* Dupilumab within 3 months prior to baseline visit.\n* Cell-depleting biologics, including rituximab, within 6 months prior to the baseline visit.\n* Other biologics within 5 half-lives (if known) or 16 weeks prior to baseline visit (whichever is longer).\n* Use of prescription moisturizers within 7 days of the baseline visit.",
    "miscellaneous_criteria": ""
}